NCT07020065

Phase 2Interventional

Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.

View on ClinicalTrials.gov ↗

Timeline

Start date: Nov 30, 2025
Primary completion: Mar 31, 2028
Completion date: Mar 31, 2030
First posted: Jun 13, 2025
Last posted: Jun 13, 2025
Enrollment: 156
Arms / groups: 2 / —
Source: AACT · ctgov ingestion

Drugs studied

gemcitabine
paclitaxel
pemetrexed
carboplatin
cemiplimab

Indications studied

Lung Neoplasms

CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.

NCT07020065

Timeline

Sponsors

Drugs studied

Indications studied